Rana McKay, MD, genitourinary oncologist at UC San Diego, joins the show to recap the clinically relevant research presented at the ASCO GU meeting. She begins with a breakdown of the ARASENS, PROpel, and MAGNITUDE trials for prostate cancer; moves to TROPHY-U-01, EV-103, and ATLANTIS trials for urothelial cancer; hits on KEYNOTE-564 for kidney cancer; and names a few other studies along the way that could move the needle in genitourinary cancers in the near future. *Plus – a surprise guest joins the show unannounced. You’ll have to listen to find out who it is!
N/A
Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding
Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. On this Healthcare Unfiltered episode, he explains who may be eligible for these tests, how to interpret results to avoid unnecessary
In this special episode, I give up the microphone to guest host Kelly Ryerson, who takes over the show asking questions about my new book “The Cancer Journey.”
